Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
HKSE - Delayed Quote HKD

CanSino Biologics Inc. (6185.HK)

Compare
35.000
-0.500
(-1.41%)
At close: February 21 at 4:08:22 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Dr. Xuefeng Yu Ph.D. Co-Founder, Executive Chairman, CEO & GM 4.25M -- 1965
Dr. Tao Zhu Ph.D. Co-Founder, Deputy GM & Chief Scientific Officer 4.74M -- 1973
Dr. Dongxu Qiu MBA, Ph.D. Co-Founder, Executive VP & Deputy GM 4M -- 1960
Dr. Shou-Bai Chao Ph.D. COO, Deputy GM & Executive Director 4.21M -- 1964
Ms. Jing Wang Chief Commercial Officer, Deputy GM & Executive Director 4.25M -- 1981
Mr. Chunlin Xin Senior Director of New Technology Department -- -- --
Mr. Yonghui Wu Vice President of Marketing -- -- --
Mr. Jin Cui Board Secretary -- -- 1987
Mr. Ming King Chiu FCIS, FCS Joint Company Secretary -- -- 1977

CanSino Biologics Inc.

401-420, Biomedical Park
4th Floor 185 South Avenue TEDA West District
Tianjin, 300457
China
86 022 5821 3600 https://www.cansinotech.com
Sector: 
Healthcare
Full Time Employees: 
1,494

Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Corporate Governance

CanSino Biologics Inc.’s ISS Governance QualityScore as of February 1, 2025 is 6. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 9; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 26, 2025 at 10:59 AM UTC - March 31, 2025 at 12:00 PM UTC

CanSino Biologics Inc. Earnings Date

Recent Events

July 13, 2022 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

688321.SS Shenzhen Chipscreen Biosciences Co., Ltd.
18.79
+3.98%
 
0013.HK HUTCHMED
25.450
+6.93%
 
600196.SS FOSUN PHARM
25.63
+0.20%
 
T14.SI Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
2.1500
+1.42%
 
2005.HK SSY Group Limited
3.320
+0.61%
 
2877.HK China Shineway Pharmaceutical Group Limited
8.440
+0.12%
 
3320.HK China Resources Pharmaceutical Group Limited
5.480
+1.29%
 
2096.HK Simcere Pharmaceutical Group Limited
7.900
+2.33%
 
4523.T Eisai Co., Ltd.
4,279.00
+0.87%
 
1558.HK HEC CJ PHARM
10.200
-1.92%